Compare BHRB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | GERN |
|---|---|---|
| Founded | 1852 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 808.3M |
| IPO Year | 2023 | N/A |
| Metric | BHRB | GERN |
|---|---|---|
| Price | $70.18 | $1.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $71.80 | $2.17 |
| AVG Volume (30 Days) | 190.8K | ★ 13.7M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | $26.91 |
| Revenue Next Year | $10.06 | $43.75 |
| P/E Ratio | $39.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.35 | $1.04 |
| 52 Week High | $73.69 | $2.01 |
| Indicator | BHRB | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 52.11 |
| Support Level | $61.32 | $1.23 |
| Resistance Level | $70.71 | $1.46 |
| Average True Range (ATR) | 1.76 | 0.09 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 46.46 | 34.72 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.